Cover Image
QR Code

Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma.

Published in:European Journal of Nuclear Medicine & Molecular Imaging Vol. 32; no. 4; pp. 458 - 470
Main Authors: Boucek, Jan, Turner, J.
Format: Journal Article
Published: Springer Nature Apr2005
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104325088&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104325088
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16197070
        NPC
      jtl: European Journal of Nuclear Medicine & Molecular Imaging
      issn: 16197070
      maglogo: N
    pubinfo:
      dt: Apr2005
      vid: 32
      iid: 4
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        104325088
        2011946337
        10.1007/s00259-004-1692-9
        104325088
      ppf: 458
      ppct: 12
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma.
      aug:
        au:
          Boucek, Jan
          Turner, J.
        affil: Department of Nuclear Medicine, Fremantle Hospital, Fremantle, WA, Australia.
      sug:
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N